|
CN108601730A
|
|
The preparation of vancomycin
|
|
WO2014194296A1
|
|
Formulations of vancomycin
|
|
MX2015005837A
|
|
Enema composition for treatment of ulcerative colitis having long term stability.
|
|
EP2836199A1
|
|
Fulvestrant formulations
|
|
US2013267489A1
|
|
Fulvestrant formulations
|
|
AU2012294423A1
|
|
Cabazitaxel formulations and methods of preparing thereof
|
|
WO2013022969A1
|
|
Docetaxel formulations with lipoic acid
|
|
WO2012021791A2
|
|
Aqueous formulation with improved stability
|
|
US7772274B1
|
|
Docetaxel formulations with lipoic acid
|
|
CA2683032A1
|
|
Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
|
|
CA2683248A1
|
|
Solubilized formulation of docetaxel
|
|
US2011092579A1
|
|
Solubilized formulation of docetaxel
|
|
WO2009111057A2
|
|
Fulvestrant formulations
|
|
AU2008269179A1
|
|
Solubilized formulation of docetaxel without Tween 80
|
|
AU2008254957A1
|
|
Ziprasidone formulations
|
|
CN101795684A
|
|
Combinations of statins and anti-obesity agent
|
|
WO2008124121A1
|
|
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
|
WO2008124122A1
|
|
Combinations of statins and anti-obesity agent and glitazones
|
|
WO2008060441A2
|
|
Stable amifostine liquid concentrate
|
|
WO2008045410A2
|
|
Alcohol free formulation of argatroban
|
